New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2014
07:41 EDTBIIBBiogen to present two-year data from Plegridy Phase 3 study at AAN meeting
Biogen Idec announced two-year data from its Phase 3 ADVANCE clinical trial for PLEGRIDY in people with relapsing forms of multiple sclerosis. These data, which will be presented at the 66th American Academy of Neurology annual meeting, indicate PLEGRIDY dosed once every two weeks demonstrated favorable results on relapse rates, magnetic resonance imaging findings and disease progression. Over two years, the safety profile of PLEGRIDY was consistent with other multiple sclerosis interferon therapies. “The two-year data from ADVANCE further establish the efficacy and safety profile of PLEGRIDY demonstrated in the first year of the pivotal trial,” said Gilmore O’Neill, vice president, Global Neurology Clinical Development at Biogen Idec. “If approved, we believe that PLEGRIDY dosed once every two weeks will provide MS patients with one of the most significant developments in the interferon class in over a decade.” ADVANCE was a two-year, Phase 3, placebo-controlled study that evaluated the efficacy and safety of PLEGRIDY administered subcutaneously. The analysis for all primary and secondary efficacy endpoints occurred at the end of year one. After the first year, patients on placebo received PLEGRIDY for the duration of the study.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent BIIB news | >>
October 24, 2014
09:16 EDTBIIBBiogen weakness creates buying opportunity, says Argus
Subscribe for More Information
October 23, 2014
06:25 EDTBIIBBiogen PML case expected to have minimal impact at Citigroup
Subscribe for More Information
October 22, 2014
16:33 EDTBIIBOn The Fly: Closing Wrap
Subscribe for More Information
13:38 EDTBIIBBiogen price target lowered to $386 from $420 at Piper Jaffray
Subscribe for More Information
12:21 EDTBIIBBiogen upgraded to Outperform from Neutral at RW Baird
Subscribe for More Information
12:09 EDTBIIBOn The Fly: Midday Wrap
Subscribe for More Information
11:38 EDTBIIBBiogen retreats after Tecfidera sales miss, patient death reported
Subscribe for More Information
11:01 EDTBIIBBiogen trading lower on slower growth, PML case, says Deutsche Bank
Deutsche Bank attributes the pullback in shares of Biogen (BIIB) to slower sequential revenue growth and the one PML case with Tecfidera disclosed on today's earnings call. Deutsche believes investors are now favoring Celgene (CELG) over Biogen due to near term headline risks. The firm says it likes Celgene more as well due its pipeline, but keeps a Buy rating on Biogen.
10:46 EDTBIIBBiogen shares defended at Morgan Stanley
Subscribe for More Information
10:42 EDTBIIBBiogen shares defended at Deutsche Bank
Subscribe for More Information
09:46 EDTBIIBBiogen falls, levels to watch
The shares are down sharply following Q3 results and a guidance boost for FY14, At the current price of $294.96, shares are lower by 9.8%. Support is at the session low at $290.94. Resistance is at $299.71.
09:21 EDTBIIBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 3.7%... iRobot (IRBT), up 12%... Six Flags (SIX), up 13%... GlaxoSmithKline (GSK), up 2%... Broadcom (BRCM), up 7%... Boston Scientific (BSX), up 4.3%... Abbott (ABT), up 1.8%... Yahoo! (YHOO), up 6%. ALSO HIGHER: Blue Earth (BBLU), up 26.4% after CEO says statements in Seeking Alpha blog are "false and misleading."... GW Pharmaceuticals (GWPH), up 5.4% after Epidiolex receives orphan designation from EMA. DOWN AFTER EARNINGS: 3D Systems (DDD), down 15%... Biogen (BIIB), down 7%... Lumber Liquidators (LL), down 13.4%... Norfolk Southern (NSC), down 3%... Angie's List (ANGI), down 8.8%. ALSO LOWER: Nanosphere (NSPH), down 33% after filing secondary, reporting preliminary Q3 revenue... Himax Technologies (HIMX), down 16% after announcing that Google (GOOG) will not exercise an additional investment option in the company... Cree (CREE), down 10.5%, downgraded at DA Davidson and Canaccord following the company's Q1 earnings results... Ocwen Financial (OCN), down 7% after downgraded to Hold at Evercore, downgraded to Neutral at BofA Merrill Lynch... VMware (VMW), down 7.8%, downgraded at Nomura and Raymond James following the company's Q3 results.
09:12 EDTBIIBBiogen down 6% after Q3 report, disclosure of patient death
Subscribe for More Information
07:08 EDTBIIBBiogen reports Q3 TECFIDERA revenues $787M
Subscribe for More Information
07:03 EDTBIIBBiogen raises FY14 adjusted EPS view to $13.45-$13.55, consensus $13.10
Still sees revenue growth 38%-41% vs. 2013, consensus $9.69B. $&D expense is expected to be approximately 20% to 21% of total revenue.
07:02 EDTBIIBBiogen reports Q3 adjusted EPS $3.80, consensus $3.46
Reports Q3 revenue $2.51B, consensus $2.48B.
October 21, 2014
15:35 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information
06:54 EDTBIIBBiogen October weekly volatility elevated into Q3 and outlook
Subscribe for More Information
October 20, 2014
07:32 EDTBIIBCubist names Perez CEO to succeed Bonney
Subscribe for More Information
October 14, 2014
11:23 EDTBIIBBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
1 | 2 | all recent BIIB news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use